¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug resistance factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾à¹°À¯¹ß¸Á¸·º´(Áõ)
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • drug-resistant
    ¾à¹°ÀúÇ×-
  • designer drug
    º¯Á¶¾à¹°
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø, °íÁ¤¾àÁø
  • gateway drug
    Åë·Î¼ö´Ü¾à¹°, ½À°üÇü¼º¾à¹°
  • generic drug name
    ÀϹݾà¸í
  • hallucinogenic drug
    ȯ°¢Á¦
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • drug interference
    ¾à¹°°£¼·
  • drug plant
    ¾àÃÊ
  • drug potentiation
    ¾à¹°°­È­ÀÛ¿ë, ¾à¹°»ó½ÂÀÛ¿ë
  • drug psychosis
    ¾à¹°Á¤½Åº´
  • drug rash
    ¾à¹°¹ßÁø, ¾àÁø
  • drug therapy
    ¾à¹°¿ä¹ý
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • drug treatment
    ¾à¹°Ä¡·á
  • drug withdrawal
    ¾à¹°±Ý´Ü
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • drug-induced hemolysis
    ¾àÁ¦À¯¹ß¿ëÇ÷
  • drug-induced hepatitis
    ¾à¹°°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • Hageman factor
    ÇϰԸ¸ÀÎÀÚ
  • Hydrostatic factor
    Á¤¼öÀÎÀÚ(ð¡â©ì×í­)
  • IGF-I(insulin-like growth factor-I)
    Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ-1
  • Luteinization -inhibiting factor
    Ȳüȭ¾ïÁ¦¿äÀÎ(üÜô÷ûùåäð¤é©ì×)
  • Macrophage colony-stimulating factor
    ´ë½Ä¼¼Æ÷Áý¶ôÇü¼ºÃËÁøÀÎÀÚ(ÓÞãÝá¬øàó¢Õªû¡à÷õµòäì×í­)à÷õµòäì×?
  • NGF=>nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • Q factor
    Å¥ ÀÎÀÚ
  • Q-factor
    Å¥-ÀÎÀÚ (ì×í­)
  • R factor
    ³»¼ºÀÎÀÚ.
  • R factor
    ³»¼ºÀÎÀÚ.
  • Rh factor
    RhÀÎÀÚ.
  • Stuart-Prower factor
    ½ºÆ©¾îÆ®-ÇÁ¶ó¿ö ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°(¼º)ÈïºÐ¾à, ¾Æµå·¹³¯¸°(¼º)ÀÚ±ØÁ¦.
  • adulterated drug
    ¼¯À½Áú¾àǰ.[¿¹¹æ]ºÎÁ¤¾àǰ(ËÓËøËâ̰).
  • alkylating agent =a. drug
    ¾ËųȭÁ¦(ð¥).
  • allergy, drug
    ¾à¹°¾Ë·¹¸£±â
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
  • antiallergic drug
    Ç׾˷¹¸£±â¾à.
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • hypocalcemic factor
    Àú(î¸)Ä®½·Ç÷Áõ(úìñø) ÀÎÀÚ(ì×í­)
  • hypoglycemic factor
    ÀúÇ÷´ç ÀÎÀÚ(î¸úìÓØì×í­)
  • initiation factor
    °³½ÃÀÎÀÚ(ËÒã·ì×í­)
  • instability factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • intrinsic factor
    ³»ÀÎÀÎÀÚ(Ò®ì×ì×í­)
  • labile factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • Laki-Lorand factor
    ¶óŰ-·Î¶õµå ÀÎÀÚ(ì×í­)
  • Lande G factor
    ¶õµ¥ G ÀÎÀÚ(ì×í­)
  • lard factor
    µ·Áö(ÔÊò·) ÀÎÀÚ(ì×í­)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • Lewis factor
    ·çÀ̽ºÀÎÀÚ(ì×í­)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • liver filtrate factor
    °£ ¿©°ú ÀÎÀÚ(ÊÜÕëΦì×í­)
  • LLD factor
    LLD ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
RTF resistance transfer factor; respiratory tract fluid
ANF alpha-naphthoflavone; American Nurses' Foundation; antineuritic factor; antinuclear factor; atrial n...
APF acidulated phosphofluoride; American Psychological Foundation; anabolism-promoting factor; animal pr...
EPF early pregnancy factor; endocarditis parietalis fibroplastica; endothelial proliferating factor; est...
HF Hageman factor; haplotype frequency; hard filled [capsule]; hay fever; head of fetus; head forward; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
IDU Injecting drug use
IDU Injecting drug users
IDU Injection drug use
IDU Injection drug users
IVDU Intravenous Drug Users
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ¾àǰ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • narcotic drug
    ¸¶¾à
    ¸ð¸£ÇÉ, ÄÚÄ«ÀÎ, ¾ÆÆí µî°ú ±× À¯µµÃ¼·Î¼­ ¹Ì·®À¸·Î °­·ÂÇÑ ÁøÅë ÀÛ¿ë°ú ¸¶Ãë ÀÛ¿ëÀ» Áö´Ï¸ç °è¼Ó »ç¿ëÇÏ¸é ½À°ü¼º°ú Ž´Ð¼ºÀÌ »ý±â°Ô ÇÏ´Â ¹°Áú. »ç¿ëÀ» Áß´ÜÇÏ¸é °Ý·ÄÇÑ ±Ý´Ü Áõ¼¼¸¦ ÀÏÀ¸ÄÑ ¸¶¾àÀ» »ç¿ëÇÏÁö ¾Ê°í´Â Á¤»óÀûÀÎ »ýȰÀ» ÇÒ ¼ö ¾ø°Ô µÇ¸ç, Á¾±¹¿¡ °¡¼­´Â À°Ã¼ÀûÀ¸·Î³ª Á¤½ÅÀûÀ¸·Î ÆóÀÎÀÌ µÇ°Ô ÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ·± ¹°ÁúÀÌ ÀÇ·á ¹× ¿¬±¸ ÀÌ¿ÜÀÇ ¸ñÀû¿¡ ³²¿ëµÇ´Â À§ÇèÀ» ¹æÁöÇϱâ À§ÇÏ¿© Á¤ÇÑ ¹ý·ü»ó ¿ë¾î°¡ ¸¶¾àÀÌ´Ù. ¸¶¾àÀº ¨ç ¾Þ¼Ó¿¡¼­ äÃëÇÏ´Â ¾ÆÆí ¾ËÄ®·ÎÀ̵å°è ¸¶¾à
  • negative drug history
    À½¼º Åõ¾à º´·Â
  • neuroleptic drug
    ½Å°æ ÀÌ¿ÏÁ¦
  • new drug application
    ½Å¾à Çã°¡ ½Åû
  • non-respiratory depressant drug
    ºñ-È£Èí ¾ïÁ¦Á¦
  • orphan drug
    Èñ±Ô ÀǾàǰ
  • OTC drug
    ÀÏ¹Ý ¸Å¾à
    over-the-counter drugÀÇ ¾àÀÚ. ÀÇ»çÀÇ Ã³¹æÀÌ ¾øÀÌ ¾à±¹¿¡¼­ ±¸ÇÒ ¼ö ÀÖ´Â ¾à.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
drug holiday Interval when a chronically medicated patient temporarily stops taking the medication; used to allow some recuperation of normal functions, to maintain sensitivity to the drug, and to reduce the likelihood of side-effects.
(05 Mar 2000)
drug hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
(12 Dec 1998)
drug implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
(12 Dec 1998)
drug incompatibility <pharmacology> The quality of not being miscible with another given substance without a chemical change.
One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction.
(12 Dec 1998)
drug-induced cholestasis <hepatology> A condition where a drug is interfering with the normal flow of bile from the liver to the gut via the biliary tract. The end result is jaundice.
Origin: Gr. Stasis = stoppage
(27 Sep 1997)
drug-induced diarrhoea <gastroenterology> Diarrhoea may be produced by several mechanisms. Laxatives may produce diarrhoea by increasing the flow of water into the intestine or by increasing the intestinal motility.
Antibiotic medications can cause diarrhoea by killing the normal bacteria that live in the intestine and help us digest our food. Some drugs produce diarrhoea as a side effect or as drug toxicity.
(27 Sep 1997)
drug-induced disease <pharmacology> A toxic reaction to or morbid condition resulting from the administration of a drug.
(05 Mar 2000)
drug-induced eosinophilic lung disease <radiology> Diffuse reticular pattern: nitrofurantoin, Loeffler-like pattern: penicillin, sulfonamides, ASA, para-ASA, imipramine, HCTZ, cromolyn sodium see: eosinophilic lung disease
(12 Dec 1998)
drug-induced hepatitis <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug.
Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives.
(27 Sep 1997)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
drug-induced tremor <neurology, pharmacology> A drug-induced condition where there is shaking (tremor) of the extremities that is increased with purposeful movement.
Drugs known to induce tremor include: theophylline, Alupent, cyclosporine, amphetamines, lithium and caffeine.
(27 Sep 1997)
drug industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
(12 Dec 1998)
drug information services Services providing pharmaceutic and therapeutic drug information and consultation.
(12 Dec 1998)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á